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Background: Surgical staging using transperitoneal laparoscopic para-aortic lymph node dissection is an
option for the pretreatment evaluation of locally advanced cervical cancer; however, its role for elderly
patients ( 65 years) remains unclear.
Methods: Elderly patients with stage IIBeIVA cervical squamous cell carcinoma who underwent trans-
peritoneal laparoscopic para-aortic lymph node dissection (TLSPAD) before radiation therapy (RT) or
concurrent chemoradiation therapy (CCRT) during 1993e2001 were included in this retrospective study.
The control group included elderly patients with the same clinical conditions, except they did not
undergo TLSPAD. Survival and major bowel complications were compared between these two groups.
Results: The TLSPAD group consisted of 19 patients (median age: 72 years; range: 65e78 years), and the
control group consisted of 37 patients (median age: 73 years; range: 65e86 years). In the TLSPAD group,
para-aortic lymph node metastasis was noted in 15.8% of patients and another 15.8% were unable to have
their lymph node laparoscopically retrieved. Although patients in the TLSPAD group demonstrated
a higher rate of receiving CCRT than the control group, neither failure-free survival nor overall survival
were statistically different between these two groups. Subsequent major bowel complications
(e.g., ﬁstula, bowel obstruction) were more frequent in the TLSPAD group (36.8%) than the control group
(10.8%; p¼ 0.032).
Conclusion: In elderly patients with locally advanced cervical squamous cell carcinoma, pretreatment
TLSPAD might not improve survival and might be associated with an increased risk of subsequent major
bowel complications. Extraperitoneal laparoscopic para-aortic lymphadenectomy might be a better
method for the pretreatment surgical staging of elderly patients because it could potentially result in
fewer bowel complications.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Cervical cancer is the second most common cancer that afﬂicts
women worldwide1. Most cases occur in developing countries
where there are no routine Papanicolaou smear screening
programs in place. In developing countries, cervical cancer is still
the leading cause of cancer death in women1.re.
, Chairman, Department of
al, 92, Section 2, Chung-Shan
ang).
iwan Society of Geriatric EmergenTreatment of cervical cancer depends largely on the FIGO stage2.
For stage IBeIIA cancer, radiation therapy (RT) and surgical treat-
ment result in similar survival rates3. For stage IIBeIVA cancer,
concurrent chemoradiation therapy (CCRT) is regarded as the
treatment of choice in most countries4e6. For stage IVB cancer,
systemic chemotherapy is the main treatment modality2.
The presence of para-aortic lymph node (PALN) metastasis
indicates a poor prognosis. In TNM staging system, PALNmetastasis
is classiﬁed as distant metastasis, i.e., M16. PALNmetastasis is noted
in 5% of stage IB cancer, 16e21% of stage II cancer, and 25e31% of
stage III cancer, respectively7.
When PALN metastasis is present, treatment usually consists of
extended-ﬁeld RT in order to treat the entire para-aortic area2,8.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of the patients in the TLSPADa group and the control group.
TLSPAD Group Control Group
Patients (no.) 19 37
Age Median: 72 years Median: 73 years
Range: 65e78 years Range: 65e86 years
Stage
IIB 10 patients 14 patients
IIIA 1 patient 1 patient
IIIB 8 patients 21 patients
IVA 0 patients 1 patient
Pretreatment image study
PAN (þ) 2 patients 1 patient
PAN (-) 13 patients 21 patients
Treatment
Pelvic RT 9 patients 31 patients
Pelvic CCRT 7 patients 5 patients
Extended-ﬁeld RT 2 patients 1 patient
Extended-ﬁeld CCRT 1 patient 0 patients
Documented treatment failure 6 patients 15 patients
Documented death 9 patients 25 patients
Failure-free survivalþ 44 mo (range: 3e95) 24 mo (range: 3e122)
Stage IIB aloneþ 58 mo (range: 3-71) 22 mo (range: 8e85)
Stage IIIB aloneþ 30 mo (range: 4e95) 27 mo (range: 3e122)
Overall survivalþ 51 mo (range: 4e95) 24 mo (range: 5e122)
Stage IIB aloneþ 54 mo (range: 4e71) 25 mo (range: 5e87)
Stage IIIB aloneþ 41 mo (range: 8e95) 24 mo (range: 5e122)
Subsequent major
bowel complications
7 patients 4 patients
Previous history of
abdominopelvic surgery
5 patients 5 patients
þ: No statistical difference.
Abbreviations: PAN, para-aortic lymph node; CCRT, concurrent chemoradiation
therapy; RT, radiation therapy.
a Transperitoneal laparoscopic para-aortic lymph node sampling.
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radiation tolerance, e.g., the small bowel, kidney, and spinal cord.
Para-aortic irradiation is usually reserved for patients with PALN
metastasis. Although high-risk patients with a high probability of
local control can beneﬁt from extended-ﬁeld RT, the routine use of
para-aortic RT for treating all high-risk patients with cervical
carcinoma is of limited value and carries the risk of severe digestive
complications9. The rate of severe complications was 9% in patients
who received extended-ﬁeld irradiation and 4.8% in thosewho only
received treatment to the pelvis9.
For these reasons, the identiﬁcation of PALN metastasis is of
clinical signiﬁcance for determining the scope of the irradiation
ﬁeld. Unfortunately, computed tomography (CT) and magnetic
resonance imaging (MRI) have low sensitivities for detecting PALN
metastasis10. PET may be a superior method for assessing the nodal
status of cervical cancer. However, its sensitivity is only about 80%11.
This implies that surgical staging is still the gold standard for PALN
assessment before administering deﬁnitive RT for the treatment of
cervical cancer.
Surgical staging for lymph node assessment may change the
treatment plan for approximately 20% of patients12. According to
National Comprehensive Cancer Network (NCCN) practice guide-
lines, surgical staging is listed as an option before CCRT for locally
advanced cervical cancer2. Surgical staging with transperitoneal
laparoscopic para-aortic lymph node sampling (TLSPAD) is
a reasonable option for determining PALN metastasis13. This is
a minimally invasive surgical procedure, and patients are able to
recover soon, which does not delay deﬁnitive RT or CCRT.
The role of TLSPAD for assessing elderly patients is still unclear.
In patients  65 years, the impact of this surgery on morbidity is
unknown, and the survival beneﬁts of TLSPAD before RT remain
undetermined. We performed a retrospective study in order to
investigate the role of TLSPAD in the management of locally
advanced (stage IIBeIVA) cervical squamous cell carcinoma in
elderly patients ( 65 years).
2. Materials and methods
The study group consisted of elderly patients ( 65 years) who
had been diagnosedwith FIGO stage IIBeIVA cervical squamous cell
carcinoma and underwent TLSPAD before deﬁnitive RT or CCRT
between February 1993 and July 2001 at our hospital.
The control group consisted of elderly patients who had been
treated for FIGO stage IIBeIVA cervical squamous cell carcinoma
without pretreatment surgical staging between February 1993 and
July 2001 at our hospital. The patients in the control group were
randomly chosen at a ratio of 2:1 to the TLSPAD group.
Regarding the RT protocol, teletherapy was administered by
linear accelerators to targeted volumes that included the primary
tumor, parametrium, and the pelvic and common iliac lymph
nodes. Para-aortic lymph nodes were included if metastases were
detected. RT was delivered by an initial 4-ﬁeld box technique
followed by a parallel-opposed technique at the time when
brachytherapy or one-phase intensity-modulated radiotherapy
(IMRT) was begun. A total of 50.4e60 Gy was administered via
28e30 fractions to the isocenter, and ﬁve daily fractions were
administered per week. High-dose intracavitary brachytherapy was
administered following the initial 30e40 Gy of 4-box RT or at the
end of IMRT. Brachytherapywas delivered to point A (HPA) at a total
dose of 30 Gy in six fractions, which was administered twice per
week using Henschke-shielded afterloading applicators and
iridium-192 as the isotope seed.
Regarding the use of CCRT, we intended to administer cisplatin
during the ﬁrst week of RT at a dose of 40 mg/m2 per week, using
a limit of no more than 70 mg/dose for up to six doses. Adequateintravenous hydration and appropriate antiemetics were adminis-
tered before and after chemotherapy. Acceptable criteria for the
administration of chemotherapy included a serum creatinine level
of < 1.5 mg/dL, absolute neutrophil count of > 1500 cells/mL, and
a platelet count of > 100,000 cells/mL.
Data were analyzed using the SPSS 19.0 statistical packages (IBM
Inc., United States). Univariate survival analyses were performed
using the KaplaneMeier method. Differences between survival
curves were measured using the log-rank-test. The level of signiﬁ-
cance was deﬁned as p < 0.05.
3. Results
The TLSPAD group consisted of 19 patients, and the control
group consisted of 37 patients. The characteristics of the patients in
these two groups are listed in Table 1.
The immediate surgical results of the TLSPAD group are listed in
Table 2. Positive para-aortic lymph node was diagnosed in 15.8% of
patients. Surgical failure, either aborting the surgery due to
technical limitations or failure to laparoscopically retrieve the
lymph node, occurred in another 15.8% of patients. Immediate
surgical complications were documented in two patients (13.3%),
including one vascular injury and one abdominal wall hematoma.
Due to the limitations of this retrospective study, the duration of
surgery was replaced by duration of anesthesia because most cases
had only documented the duration of anesthesia without noting
the duration of surgery.
Age was similar in both groups. Although the TLSPAD group
demonstrated a slightly higher proportion of stage IIB cancer
(52.6%, 10 of 19 patients) than the control group (37.8%, 14 of 37
patients), the proportion of patients with positive para-aortic
lymph node based on pretreatment image studies was higher in
the TLSPAD group (15.4%; 2 of 13 cases had assessable documents)
Table 2
Immediate surgical outcomes of the patients in the TLSPADa group.
Total case number 19 patients
Surgical failure 3 patients
Positive PANþ metastasis 3 patients
Number of retrieved PANþ Median: 6 patients; range: 0e17 patients
Time interval from
laparoscopy to irradiation
Median: 14 mo; range: 2e50 mo
Immediate surgical complications 2 patients
Duration of anesthesia Median: 120 min; range: 35e270 min
Blood loss Median: 100 mL; range: 10e500 mL
þ Para-aortic lymph node.
a Transperitoneal laparoscopic para-aortic lymph node sampling.
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ments) (Table 1). False-positive assessment of para-aortic lymph
node metastasis by CT scan was noted in one patient in the TLSPAD
group. False-negative assessment of para-aortic lymph node
metastasis (i.e., subsequent solitary para-aortic relapse) was noted
in one patient of the TLSPAD group and one patient of the control
group.
Deﬁnitive treatment was more intensive in the TLSPAD group.
CCRT was performed on 42.1% (8 of 19 patients) of the patients in
the TLSPAD group and 16.1% (5 of 31) of patients in the control
group. Extended-ﬁeld irradiation (including RT alone or CCRT) was
performed on 15.8% (3 of 19) of patients in the TLSPAD group and
2.7% (1 of 37) of patients in the control group.
Treatment failure (i.e., disease progression or relapse) was
documented in 36.8% (7 of 19) of patients in the TLSPAD group and
40.5% (15 of 37) of patients in the control group, respectively. In the
TLSPAD group, three patients developed locoregional recurrence:
one case of peritoneal recurrence, one case of distant recurrence
(lung), and two cases of para-aortic with distant recurrence (neck
or liver). The two patients with para-aortic and distant failure,
demonstrated neither para-aortic lymphadenopathy on imaging
nor positive para-aortic lymph nodes on pathological examination.
In the control group, seven patients developed locoregional failure,
ﬁve cases of distant recurrence, one case of combination vaginal
and liver relapse, and two cases of para-aortic involvement with or
without liver metastasis. The median failure-free survival period
was 44 months (range: 3e95 months) for the TLSPAD group and 23
months (range: 3e122 months) for the control group, respectively.Fig. 1. A. Comparison of failure-free survival rates between patients who did not undergo lap
staging (labeled as “LSC staging (þ)”) according to the results of the Kaplan-Meier metho
undergo laparoscopic staging (labeled as “LSC staging (-)”) and those who did undergo lapa
Meier method and log-rank test.Although the median failure-free survival period of the control
group appears to be shorter, there was no statistical difference
between these two groups (p¼ 0.276; Fig. 1A).
Death was documented in 47.4% (9 of 19) of the patients in the
TLSPAD group and 67.6% (25 of 37) of the patients the control
group (Table 1). In the TLSPAD group, one patient died of sepsis
after administering chemotherapy to treat recurrence, one patient
died of pneumonia, and seven died of cervical cancer. In the
control group, one patient died of sepsis after administering
chemotherapy to treat recurrence, eight patients died of other
medical diseases or surgical complications, and 16 died of cervical
cancer. The median overall survival period was 51 months (range:
4e95 months) for the TLSPAD group and 24 months (range:
5e122) for the control group, respectively (Table 1). Although the
median overall survival period of the control group appears
shorter, there was no statistical difference between these two
groups (p¼ 0.372; Fig. 1B).
When only stage IIB or IIIB cancers were compared, neither
failure-free survival nor overall survival were statistically different
between the TLSPAD and control groups (Table 1; Figs. 2A,2B,3A,3B).
Subsequent major bowel complications (e.g., ﬁstula, obstruc-
tion, radiation colitis requiring colectomy) were documented in
36.8% of the patients in the TLSPAD group, in contrast to 10.8% of
patients in the control group (p¼ 0.032; Table 1). Treatments
administered to the seven patients in the TLSPAD group with
subsequent major bowel complications included pelvic RT in four
patients, pelvic CCRT in two patients, and extended-ﬁeld RT in one
patient. Treatments administered to the four patients with subse-
quent major bowel complications in the control group included
pelvic RT in three patients and extended-ﬁeld RT in one patient. A
history of previous abdominal pelvic surgery was only noted in one
patient with subsequent major bowel complications in the TLSPAD
group and one patient in the control group.
4. Discussion
Any clinical practice that is considered appropriate for younger
patients may not necessarily be applicable for use on elderly
patients. Elderly patients with locally advanced cervical cancer are
comparatively more fragile than younger patients. In the current
series, a signiﬁcant proportion of elderly patients died of otheraroscopic staging (labeled as “LSC staging (-)”) and those who did undergo laparoscopic
d and log-rank test. B. Comparison of overall survival between patients who did not
roscopic staging (labeled as “LSC staging (þ)”) according to the results of the Kaplan-
Fig. 2. A. Comparison of the failure-free survival rates of stage IIB patients who did not undergo laparoscopic staging (labeled as “LSC staging (-)”) and those who did undergo
laparoscopic staging (labeled as “LSC staging (þ)”) according to the results of the Kaplan-Meier method and log-rank test. B. Comparison of the overall survival rates of stage IIB
patients who did not undergo laparoscopic staging (labeled as “LSC staging (-)”) and those who did undergo laparoscopic staging (labeled as “LSC staging (þ)”) according to the
results of the Kaplan-Meier method and log-rank test.
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than cervical cancer itself. Two patients (3.6%) died of
chemotherapy-related sepsis, and nine patients (16%) died of
intercurrent medical problems.
In our series, only 23.2% (13 of 56) of patients underwent CCRT
as their deﬁnitive treatment. This low rate may be due to the fact
that CCRT was not the standard treatment until 1999 when several
large randomized trials were published that demonstrating its
efﬁcacy4,14,15. Our patients were treated between 1993e2001.
Another reason why CCRT was not used to treat some elderly
patients was due to the presence of intercurrent medical problems.
One beneﬁt of TLSPAD is that it decreases the risk of false-
positive assessment of para-aortic lymph nodes that can result
from the use of imaging studies, which may result in unnecessary
irradiation to the para-aortic area and potentially increase bowel
morbidity. In the current series, a 67-year-old patient with stage
IIIB cancer received a false-positive assessment of para-aorticFig. 3. A. Comparison of the failure-free survival rates of stage IIIB patients who did not u
laparoscopic staging (labeled as “LSC staging (þ)”) according to the results of the Kaplan-M
patients who did not undergo laparoscopic staging (labeled as “LSC staging (-)”) and those
results of the Kaplan-Meier method and log-rank test.lymph node metastasis following a CT scan. She underwent
TLSPAD, but a pathological examination revealed no positive lymph
nodes. The patient underwent pelvic CCRT and remained in
complete remission for 70 months until she died of pneumonia.
On the other hand, TLSPAD still carries the potential risk of
producing false-negative results. In our series, a 68-year-old patient
with stage IIB cancer did not demonstrate para-aortic lymph node
metastasis by either CT scan or TLSPAD. Unfortunately, solitary
relapses in the para-aortic area and neck were noted 58 months
later. This ﬁnding indicates that for surgical staging, a more thor-
ough para-aortic lymphadenectomy might be more appropriate
than sampling of the para-aortic lymph nodes alone.
In the current series, neither failure-free survival nor overall
survival were statistically different between the TLSPAD group and
the control group, although a higher proportion of patients in the
TLSPAD underwent CCRT. As far as we know, CCRT has been proven
to be more effective than RT alone for treating locally advancedndergo laparoscopic staging (labeled as “LSC staging (-)”) and those who did undergo
eier method and log-rank test. B. Comparison of the overall survival rates of stage IIIB
who did undergo laparoscopic staging (labeled as “LSC staging (þ)”) according to the
T.-C. Chen et al.210cervical cancer4,14,15. This implies that pretreatment TLSPAD might
not beneﬁt the survival rate of elderly patients with locally
advanced cervical squamous cell carcinoma.
Subsequent major bowel complications occurred more
frequently in the TLSPAD group (36.8%; 7 of 19 patients) than in the
control group (10.8%; 4 of 37 patients). Most patients who devel-
oped subsequent major bowel complications also underwent pelvic
RT without concurrent chemotherapy as their primary treatment (4
of 7 patients in the TLSPAD group and 3 of 4 patients in the control
group). This indicates that the reason why the TLSPAD group
demonstrated a higher proportion of subsequent major bowel
complications was not due to the modality of the primary treat-
ment, but most likely due to the surgical procedures required by
TLSPAD itself. The surgeries required for TLSPAD might not reduce
the subsequent risk of developing bowel complications. In the
current series, which spans 1993e2001, all of the TLSPAD proce-
dures were performed by the same surgeons, and all seven patients
with subsequent bowel complications underwent TLSPAD between
1998e2000 after the surgeons had accumulated experience per-
forming TLSPAD. The better method for the surgical staging of
elderly patients with locally advanced cervical cancer might be
laparoscopic extraperitoneal para-aortic lymphadenectomy, which
theoretically results in a further decrease in bowel
complications16e21.
In conclusion, when managing elderly patients with locally
advanced cervical squamous cell carcinoma, pretreatment TLSPAD
might not improve either failure-free survival nor overall survival.
Instead, TLSPAD might be associated with an increased risk of
subsequent major bowel complications in this population. The
decision toperformTLSPADonelderlypatientswith locallyadvanced
cervical squamous cell carcinoma should be made with caution.
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